Sander van Doorn

939 total citations · 1 hit paper
40 papers, 558 citations indexed

About

Sander van Doorn is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Epidemiology. According to data from OpenAlex, Sander van Doorn has authored 40 papers receiving a total of 558 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cardiology and Cardiovascular Medicine, 7 papers in Internal Medicine and 6 papers in Epidemiology. Recurrent topics in Sander van Doorn's work include Atrial Fibrillation Management and Outcomes (18 papers), Cardiac Arrhythmias and Treatments (8 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Sander van Doorn is often cited by papers focused on Atrial Fibrillation Management and Outcomes (18 papers), Cardiac Arrhythmias and Treatments (8 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Sander van Doorn collaborates with scholars based in Netherlands, United States and Germany. Sander van Doorn's co-authors include Arno W. Hoes, Frans H. Rutten, Geert‐Jan Geersing, Karel G.M. Moons, Simone Lemeer, Albert J. R. Heck, Paul M.P. van Bergen en Henegouwen, Marc Baldus, Siddarth Narasimhan and Willie J. C. Geerts and has published in prestigious journals such as Cell, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Sander van Doorn

37 papers receiving 551 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial

2023 77 citations Sander van Doorn, Melchior C. Nierman et al. profile →

Peers

Sander van Doorn

CCM

SPECT

EPIDE

Stefaan Rossenu Belgium

Emma Magavern United Kingdom

Michael E. Barfield United States

Phillip R. Dawkins United States

L Hands United Kingdom

John J. Skinner United States

Hua Liu China

Idan Roifman Canada

Amanda L. Patrick United States

Robert C. Ireton United States

Stefaan Rossenu Belgium

Sander van Doorn

113 ×0.5

CCM

153 ×1.2

20 ×0.2

SPECT

96 ×1.3

EPIDE

53 ×0.9

Citations per year, relative to Sander van Doorn Sander van Doorn (= 1×) peers Stefaan Rossenu

Countries citing papers authored by Sander van Doorn

Since Specialization

Citations

This map shows the geographic impact of Sander van Doorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sander van Doorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sander van Doorn more than expected).

Fields of papers citing papers by Sander van Doorn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sander van Doorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sander van Doorn. The network helps show where Sander van Doorn may publish in the future.

Co-authorship network of co-authors of Sander van Doorn

This figure shows the co-authorship network connecting the top 25 collaborators of Sander van Doorn. A scholar is included among the top collaborators of Sander van Doorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sander van Doorn. Sander van Doorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Royen, Florien S van, et al.. (2024). Additional predictors of stroke and transient ischaemic attack in BEFAST positive patients in out-of-hours emergency primary care. PLoS ONE. 19(9). e0310769–e0310769.

Royen, Florien S van, Maarten van Smeden, Sander van Doorn, Frans H. Rutten, & Geert‐Jan Geersing. (2024). Predictive factors of clot propagation in patients with superficial venous thrombosis towards deep venous thrombosis and pulmonary embolism: a systematic review and meta-analysis. BMJ Open. 14(4). e074818–e074818. 1 indexed citations

Hond, Anne de, Sjoerd de Vries, Richard Bartels, et al.. (2024). Don't be misled: 3 misconceptions about external validation of clinical prediction models. Journal of Clinical Epidemiology. 172. 111387–111387. 21 indexed citations

Geersing, Geert‐Jan, Martin E W Hemels, Michiel Rienstra, et al.. (2023). Integrated care in patients with atrial fibrillation- a predictive heterogeneous treatment effect analysis of the ALL-IN trial. PLoS ONE. 18(10). e0292586–e0292586. 9 indexed citations

Pisters, Ron, et al.. (2023). Screening over 100 000 patients in 39 general practices in the Netherlands for anticoagulation underprescription in atrial fibrillation: a descriptive, cross-sectional study. BMJ Open. 13(8). e072655–e072655. 2 indexed citations

Royen, Florien S van, Maarten van Smeden, Pauline Slottje, et al.. (2022). Cardiovascular vulnerability predicts hospitalisation in primary care clinically suspected and confirmed COVID-19 patients: A model development and validation study. PLoS ONE. 17(4). e0266750–e0266750. 4 indexed citations

Boer, Annemarijn R de, Sander van Doorn, Arno W. Hoes, et al.. (2022). Atrial fibrillation: trends in prevalence and antithrombotic prescriptions in the community. Netherlands Heart Journal. 30(10). 459–465. 3 indexed citations

Bots, Michiel L., et al.. (2022). Differences in Symptom Presentation in Women and Men with Confirmed Lower Limb Peripheral Artery Disease: A Systematic Review and Meta-Analysis. European Journal of Vascular and Endovascular Surgery. 63(4). 602–612. 21 indexed citations

Royen, Florien S van, et al.. (2021). COVID-19-isolatiespreekuren tijdens de ‘eerste golf’. Huisarts en Wetenschap. 1–7. 1 indexed citations

10.

Exalto, Lieza G., et al.. (2021). Call Characteristics of Patients Suspected of Transient Ischemic Attack (TIA) or Stroke During Out-of-Hours Service: A Comparison Between Men and Women. Frontiers in Neurology. 12. 669090–669090. 1 indexed citations

11.

Takada, Toshihiko, Sander van Doorn, Sameer Parpia, et al.. (2020). Diagnosing deep vein thrombosis in cancer patients with suspected symptoms: An individual participant data meta‐analysis. Journal of Thrombosis and Haemostasis. 18(9). 2245–2252. 7 indexed citations

12.

Takada, Toshihiko, Pauline Heus, Sander van Doorn, et al.. (2020). Strategies to reduce the use of low-value medical tests in primary care: a systematic review. British Journal of General Practice. 70(701). e858–e865. 9 indexed citations

13.

Doorn, Sander van, Arno W. Hoes, Melchior C. Nierman, et al.. (2019). Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial. BMJ Open. 9(12). e032488–e032488. 11 indexed citations

14.

Doorn, Sander van, et al.. (2018). Adaptive Resistance to EGFR-Targeted Therapy by Calcium Signaling in NSCLC Cells. Molecular Cancer Research. 16(11). 1773–1784. 12 indexed citations

15.

Doorn, Sander van, et al.. (2018). Effectiveness of CHA2DS2-VASc based decision support on stroke prevention in atrial fibrillation: A cluster randomised trial in general practice. International Journal of Cardiology. 273. 123–129. 18 indexed citations

16.

Geersing, Geert‐Jan, Noémie Kraaijpoel, Harry R. Büller, et al.. (2018). Ruling out pulmonary embolism across different subgroups of patients and healthcare settings: protocol for a systematic review and individual patient data meta-analysis (IPDMA). SHILAP Revista de lepidopterología. 2(1). 10–10. 4 indexed citations

17.

Doorn, Sander van, Thomas P. A. Debray, Femke Kaasenbrood, et al.. (2017). Predictive performance of the CHA2DS2‐VASc rule in atrial fibrillation: a systematic review and meta‐analysis. Journal of Thrombosis and Haemostasis. 15(6). 1065–1077. 27 indexed citations

18.

Doorn, Sander van, et al.. (2017). The effects of misclassification in routine healthcare databases on the accuracy of prognostic prediction models: a case study of the CHA2DS2-VASc score in atrial fibrillation. SHILAP Revista de lepidopterología. 1(1). 18–18. 11 indexed citations

19.

Kaplan, Mohammed, Siddarth Narasimhan, Cecilia de Heus, et al.. (2016). EGFR Dynamics Change during Activation in Native Membranes as Revealed by NMR. Cell. 167(5). 1241–1251.e11. 145 indexed citations

20.

Doorn, Sander van, et al.. (2011). Psychopathology of adolescent detained versus psychiatric inpatient females. Psychiatry Research. 195(3). 129–133. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact